Jeffrey Stavenhagen

Jeffrey Stavenhagen is a seasoned biotech executive and the Chief Scientific Officer at Windward Bio, with over 20 years of experience leading drug discovery. He is a recognized expert in advancing therapeutic candidates, particularly monoclonal antibodies, into clinical development. Jeffrey earned his PhD in Molecular Biology from Columbia University.

Beyond his scientific leadership, Jeffrey maintains a keen interest in the broader biotechnology industry, following market trends and major players like Amgen. Based on his time at Carnegie Mellon University in Pittsburgh, he may follow local sports teams.

As the first employee at MacroGenics, he built a novel antibody engineering platform that resulted in Margenza®, one of the first Fc optimized monoclonal antibodies on the market.